Biomarkers & Precision Medicine USA Congress
October 3 - 4, 2016 - Oxford UKOxford Global
g.alonso@oxfordglobal.co.uk
Phone:+44 (0) 1865 248 455
Oxford Global is proud to present its Biomarkers and Precision Medicine USA Congress 2016, 3-4 Oct 2016, Boston, USA. Our renowned congress will bring together over 250 attendees from pharmaceutical and biotechnology companies as well as academia. The global biomarkers market will be valued at $24.10 Billion in 2015. It is expected to grow at a CAGR of 13.58% to reach $45.55 Billion by 2020 making it one of the fastest growing sectors within the pharmaceutical industry. The congress will include representatives from the top pharmaceutical companies including Bayer, Pfizer, Roche, BMS, Merck, OncoMed, Takeda and more. Our expert speaker panel will also consist of renowned academics and smaller pharmaceutical companies who will discuss their insights and case studies. The 5 Interactive Streams include: • Biomarkers in Drug Discovery and Development – Translation and Precision Medicine in Auto-Immune Diseases, CNS, Oncology, and Infectious Diseases • Personalised Medicine, Companion Diagnostics & Patient Testing • Innovations In Biomarker Research – Informatics, Data Management, Assay Development, Imaging Technologies • Biomarker in Clinical Development & Clinical Trials • Clinical Diagnostics, NGS & Genomic Markers and Genetic Testing The 2 day exciting programme covers case studies from a range of therapeutic areas including, oncology, immune-oncology, cardiovascular diseases, metabolic diseases, autoimmune diseases, fibrotic disorders, diabetes and more in the pre-clinical and clinical arena. Do not miss out on the latest development sin companion diagnostics and precision medicine. Experts will also discuss presentations on NGS as a choice of diagnostics, microRNAs as a potential circulating biomarker of drug-induced liver injury and the potential of metabolomics profiling to understand disease process and therapy.